# Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

> **NCT04657198** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 126 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA investigational vaccine (GSK3844766A)

## Key facts

- **NCT ID:** NCT04657198
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2021-06-03
- **Final completion:** 2021-10-25
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2022-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657198, "Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04657198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*